PD Frontline (Part of RAPSODI GD) Remote Assessment of People With Parkinson's

Last updated: November 28, 2023
Sponsor: University College London Hospitals
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT06151002
173275
  • Ages 18-90
  • All Genders

Study Summary

PD Frontline (part of RAPSODI GD) is an online study observational study with the goal of bringing People with Parkinson's to the frontline of research by getting them trial ready. To do this, participants are offered genetic sequencing for the GBA and LRRK2 gene with an at-home saliva collection kit.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Formal diagnosis of Parkinson Disease

Exclusion

Exclusion Criteria:

  • Confirmation that the individual carries a GBA variant (GBA positive). Theseindividuals will be referred to sister-study, RAPSODI.
  • History of Parkinsonism (progressive supranuclear palsy, multiple system atrophy,traumatic, manganese toxicity, postencephalitic, vascular PD; drug induced PD;corticobasal degeneration)
  • Individuals with another neurological disorder including: dementia, movementdisorders, and motor neurone disease.
  • Individuals on drugs known to be associated with parkinsonism, including neurolepticagents (Amisulpride, Chlorpromazine Hydrochloride, Flupenthixol, FluphenazineHydrochloride, Haloperidol, Methotrimeprazine, Levomepromazine, Olanzapine,Oxypertine, Pericyazine, Perphenazine, Pimozide, Pipotiazine, Prochlorperazine,Promazine Hydrochloride, Reserpine, Risperidone, Sulpiride, Thioridazine,Trifluoperazine, Zuclopenthixol acetate, Zotepine), plus Bupropion, , Lithium,Methyldopa, Metoclopramide and Sodium Valproate).

Study Design

Total Participants: 4800
Study Start date:
February 15, 2020
Estimated Completion Date:
August 20, 2040

Study Description

PD Frontline is an online one-time questionnaire based study with the purpose of identifying potential candidates for gene targeted trials and observational studies.

Once the questionnaire is completed, the participant is sent a saliva collection kit in the post to provide a sample for genetic testing. The genes tested for are GBA1, the most common risk factor gene for Parkinson's, and LRRK2.

Once tested, the participant is informed of their results and kept up-to-date with any studies or trials for which they may be eligible.

Connect with a study center

  • University College London (UCL)

    London, NW3 2PF
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.